Overview
CLPT market data
Price History
CLPT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.90 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -71.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.27 – $30.10 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $471.1M · P/B 14.52 · P/S 11.60.
Company News
Crude Oil Down Over 5%; McDonald's Earnings Top ViewsBenzinga · Aug 4, 2026, 4:55 PM
ClearPoint Neuro shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY26 sales guidance below estimates.Benzinga · Aug 4, 2026, 12:45 PM
Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Aug 4, 2026, 12:04 PM
Why Palantir Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving PremarketBenzinga · Aug 4, 2026, 8:42 AM
ClearPoint Neuro Lowers FY2026 Sales Guidance from $52.000M-$56.000M to $48.000M-$52.000M vs $53.133M EstBenzinga · Aug 3, 2026, 8:12 PM
ClearPoint Neuro Q2 EPS $(0.38) Misses $(0.29) Estimate, Sales $10.880M Miss $12.733M EstimateBenzinga · Aug 3, 2026, 8:10 PM
ClearPoint Neuro Highlights Partner Aspen Neuroscience’s RMAT Designation From FDA For Parkinson’s Therapy, SasineprocelBenzinga · Jul 31, 2026, 8:06 PM
B. Riley Securities Maintains Buy on ClearPoint Neuro, Raises Price Target to $30Benzinga · Jun 18, 2026, 6:00 PM
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On WednesdayBenzinga · Jun 17, 2026, 2:20 PM
ClearPoint Neuro Collaborates With SONOCARELAB To Tap Focused Ultrasound MarketBenzinga · May 27, 2026, 8:40 PM